These results provide a clue that the differential modulation of mGluR5 in both neuronal excitotoxicity by MTEP inhibition and microglia inflammation by CHPG activation depending on the pathologic situation suggests a potential therapeutic strategy for PD in future human clinical trials. Here, GRM5 is linked to Parkinson disease.